Robert Mentz, MD

Co-Editor-in-Chief @JCardFail | Chief of the HF Section @DukeHealth | Trialist @DCRInews | Father of 3

[Journal of Cardiac Failure @JCardFail]

In HELIOS-B, vutrisiran slowed renal decline in ATTR-CM: fewer ≥40% eGFR drops vs placebo (12.7% vs 21.2%).

Benefits on CV outcomes were consistent across kidney function, even in advanced CKD.

Improves not just CV outcomes but has renal benefits🫀🧪

https://t.co/Bw3XMvW03l

[Robert Mentz, MD @robmentz]

Interested in CV clinical trials? Tremendous insights shared by the ANTHEM-HF investigators about RCT complexity after the sponsor terminated the study early
@dranulala @DrMarthaGulati @mkonstam @SVRaoMD @DrCaliff_FDA @coconnormd
https://t.co/8mJ9HCxmtV

[Journal of Cardiac Failure @JCardFail]

Cardiac sarcoidosis: beyond steroids?

The REPAIR-CS trial is testing rilonacept (IL-1 blockade) added to standard therapy, with FDG-PET inflammation as the primary endpoint—marking a shift toward targeted, mechanism-based treatment.🫀

🔗 https://t.co/Mh3Pgtfhlq

[Duke Clinical Research Institute @DCRINews]

Congratulations to the latest DCRI Fellowship Program cohort! Since 1996, the program has provided advanced clinical research training 300+ fellows. Learn more: https://t.co/9xWmSyUubP #ClinicalResearch #Mentorship

[HFSA @HFSA]

ICYMI 📘

The latest @JCardFail Focus Issue explores inflammatory and infiltrative cardiomyopathies, including myocarditis, amyloidosis, sarcoidosis, AI applications, patient-centered outcomes, and more.

Featuring guest editors Drs. Nisha A. Gilotra, Mathew Maurer and Emer Joyce.

Plus, a new episode of #HFBeat is coming soon, featuring more insights from this issue.

🔗 Explore the issue: https://t.co/J8R3fENlcE

@robmentz @dranulala

[Journal of Cardiac Failure @JCardFail]

When should we biopsy for cardiac sarcoidosis? In ILLUMINATE-CS, EMB positivity (~22%) was directionally associated with established predictors (MIDFIN). Novel predictors: septal thickness, FDG-PET burden, BNP). EMBx yield rose stepwise with number of criteria.

🧵

[Satoshi Shoji, MD, PhD @SS_cardiol]

Thrilled to share that our paper is out in @NEJMEvidence.

Using a Weighted Composite Endpoint (WCE), we analyzed AFib trial data and assessed DOAC effects through a patient preference-informed metric.

Grateful to all mentors and collaborators!
https://t.co/RIWLFV4TSq

[HF Collaboratory @hfcollaboratory]

Now in the @JCardFail, #HFC members @TheHeartBeat3 @JavedButler1 @LindenfeldJoann et al present the design and rationale of the BENEFIT-HF trial evaluating baroreflex activation therapy in symptomatic HFrEF and HFmrEF.

https://t.co/djExyBhOBj

[Journal of Cardiac Failure @JCardFail]

The latest State of the Art Review looks at Immune-mediated pericardial & myocardial syndromes as unified spectrum: linking 🧬 susceptibility, 🌍 triggers & systemic inflammation, with integrated diagnostics & expanding therapies (incl. biologics).

🔗 https://t.co/7nE7hAHoCR

[HF Collaboratory @hfcollaboratory]

Now in the @JCardFail, #HFC members present a practical Bayesian framework for survival analysis in HF clinical trials.

The study highlights how Bayesian methods may improve interpretability and incorporate prior evidence across studies.
https://t.co/p08pweYq8z

[Journal of Cardiac Failure @JCardFail]

Acute myocarditis: who is truly at risk?

In a real-world cohort, most patients had favorable outcomes (~88% event-free at 10 yrs).

But higher risk was linked to age, HF symptoms and LV hypokinesia, highlighting the value of early bedside assessment.🫀📊

https://t.co/lTnRvz2lli

[Andrew J Sauer MD @AndrewJSauer]

@gcfmd @drbennisahmed @SJGreene_md @JavedButler1 @UoGHeartFailure @JamesCFangMD @HFSA @mvaduganathan @ankeetbhatt @robmentz @FudimMarat And we are exploring this further (simultaneous early initiation of nsMRA plus SGLT2i) vs usual care in acute HF irrespective of EF: stay tuned for CONFIRMATION-HF, we are nearly 40% enrolled globally in this 1,500 patient RCT.

[Gregg Fonarow MD @gcfmd]

Cardiovascular and Renal Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis https://t.co/Qe1WuLCLOb

@MushoodCh @FudimMarat @SJGreene_md

[Marat Fudim, MD MHS @FudimMarat]

Not too late to register! Key note speaker--> @NMHheartdoc

And many guest speakers @RyanTedfordMD @AminYehyaMD

Over 30 exhibitors, Hands on Sessions and ...

June 6 in Durham https://t.co/FNDkxvp1Cj

@robmentz @Steph_BarnesNP @richa_agarwalMD @manesh_patelMD @DukeHrtFailure

[European Society of Cardiology @escardio]

From the congress to my clinic - what to take home from #HeartFailure26?

Join Brenda Moura and @robmentz, hosted by Felix Lindberg, as they translate the most impactful science from Heart Failure 2026 into practical clinical insights for everyday care.
A concise, expert-led discussion connecting emerging evidence with real-world heart failure management.

#HeartFailure #Cardiology #ESCTV

[Jesús Álvarez-García @j_alvarezgarcia]

Fantastic days with friends in #Barcelona #heartfailure2026. See you in #London!

[HFSA @HFSA]

New @JCardFail Focus Issue 📘

This month’s issue explores inflammatory & infiltrative cardiomyopathies—from the “diagnostic odyssey” to AI-driven insights and evolving risk stratification.

🔗 Explore the May Focus Issue: https://t.co/AadOCw9byC

@robmentz @dranulala

[HF Collaboratory @hfcollaboratory]

Last two days at ESC Heart Failure Congress 2026 ❤️

Excited to see #HFC members and colleagues leading conversations on the latest advances in HF research, innovation, and patient care.

If you’re in Barcelona, don’t miss these final sessions. #HeartFailure2026 #ESCHF26

[Robert Mentz, MD @robmentz]

#HFcongress26 off to a roaring success 😊

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Best part of #HeartFailure2016 will always be the people!

Thanks for not letting me fall asleep from jet lag right away @robmentz @ShelleyZieroth
#functionnotfailure

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Best part of #HeartFailure2016 will always be the people!

Thanks for not letting me fall asleep from jet lag right away @robmentz @ShelleyZieroth
#functionnotfailure